Evidence map›Paper›PMID 31125283›Full record

ArticleJournal of oncology practice2019

Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach.

Francesco Perrone, Massimo Di Maio, Fabio Efficace, Ciro Gallo, Diana Giannarelli, Vincenzo Montesarchio, Silvia Riva

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Journal of oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Francesco PerroneFrancesco Perrone, MD, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Massimo Di Maio, MD, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy; Fabio Efficace, PhD, Gruppo Italiano Malattie Ematologiche dell'Adulto Onlus, Rome, Italy; Ciro Gallo, MD, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Italy; Diana Giannarelli, MSc, Istituto Regina Elena, Rome, Italy; Vincenzo Montesarchio, MD, AORN Ospedali dei Colli, Naples, Italy; and Silvia Riva, PhD, University of Wolverhampton, Wolverhampton, United Kingdom.
Massimo Di MaioFrancesco Perrone, MD, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Massimo Di Maio, MD, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy; Fabio Efficace, PhD, Gruppo Italiano Malattie Ematologiche dell'Adulto Onlus, Rome, Italy; Ciro Gallo, MD, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Italy; Diana Giannarelli, MSc, Istituto Regina Elena, Rome, Italy; Vincenzo Montesarchio, MD, AORN Ospedali dei Colli, Naples, Italy; and Silvia Riva, PhD, University of Wolverhampton, Wolverhampton, United Kingdom.
Fabio EfficaceFrancesco Perrone, MD, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Massimo Di Maio, MD, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy; Fabio Efficace, PhD, Gruppo Italiano Malattie Ematologiche dell'Adulto Onlus, Rome, Italy; Ciro Gallo, MD, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Italy; Diana Giannarelli, MSc, Istituto Regina Elena, Rome, Italy; Vincenzo Montesarchio, MD, AORN Ospedali dei Colli, Naples, Italy; and Silvia Riva, PhD, University of Wolverhampton, Wolverhampton, United Kingdom.
Ciro GalloFrancesco Perrone, MD, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Massimo Di Maio, MD, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy; Fabio Efficace, PhD, Gruppo Italiano Malattie Ematologiche dell'Adulto Onlus, Rome, Italy; Ciro Gallo, MD, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Italy; Diana Giannarelli, MSc, Istituto Regina Elena, Rome, Italy; Vincenzo Montesarchio, MD, AORN Ospedali dei Colli, Naples, Italy; and Silvia Riva, PhD, University of Wolverhampton, Wolverhampton, United Kingdom.
Diana GiannarelliFrancesco Perrone, MD, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Massimo Di Maio, MD, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy; Fabio Efficace, PhD, Gruppo Italiano Malattie Ematologiche dell'Adulto Onlus, Rome, Italy; Ciro Gallo, MD, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Italy; Diana Giannarelli, MSc, Istituto Regina Elena, Rome, Italy; Vincenzo Montesarchio, MD, AORN Ospedali dei Colli, Naples, Italy; and Silvia Riva, PhD, University of Wolverhampton, Wolverhampton, United Kingdom.
Vincenzo MontesarchioFrancesco Perrone, MD, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Massimo Di Maio, MD, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy; Fabio Efficace, PhD, Gruppo Italiano Malattie Ematologiche dell'Adulto Onlus, Rome, Italy; Ciro Gallo, MD, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Italy; Diana Giannarelli, MSc, Istituto Regina Elena, Rome, Italy; Vincenzo Montesarchio, MD, AORN Ospedali dei Colli, Naples, Italy; and Silvia Riva, PhD, University of Wolverhampton, Wolverhampton, United Kingdom.
Silvia RivaFrancesco Perrone, MD, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy; Massimo Di Maio, MD, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy; Fabio Efficace, PhD, Gruppo Italiano Malattie Ematologiche dell'Adulto Onlus, Rome, Italy; Ciro Gallo, MD, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Italy; Diana Giannarelli, MSc, Istituto Regina Elena, Rome, Italy; Vincenzo Montesarchio, MD, AORN Ospedali dei Colli, Naples, Italy; and Silvia Riva, PhD, University of Wolverhampton, Wolverhampton, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsNeoplasms, Second PrimaryCost of IllnessHumans

Identifiers

PMID31125283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.